{"References": [{"title": "Efficacy and safety of the CFTR potentiator ivacaftor in patients with cystic fibrosis and a G551D mutation", "authors": "Bonnie W. Ramsey, Jane Davies, Noreen A. McElvaney, Eitan Kerem, Stuart Elborn, Frank J. McKone, Michael W. Wainwright, Scott C. Bell, Felix Ratjen, Isabelle Sermet-Gaudelus, Margaret M. Rowe, Zhaohui Dong, Xiaohong Wang, Michael J. Tullis, Michael R. Moss, Steven M. Campbell, Michael X. Xuan, Robert J. Johnson", "journal": "New England Journal of Medicine", "year": "2011", "volumes": "365", "first page": "1663", "last page": "1672", "DOI": "10.1056/NEJMoa1105185"}, {"title": "Lumacaftor–ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR", "authors": "Stuart Elborn, Frank J. McKone, Eitan Kerem, Scott C. Bell, Felix Ratjen, Isabelle Sermet-Gaudelus, Margaret M. Rowe, Zhaohui Dong, Xiaohong Wang, Michael J. Tullis, Michael R. Moss, Steven M. Campbell, Michael X. Xuan, Robert J. Johnson", "journal": "New England Journal of Medicine", "year": "2015", "volumes": "373", "first page": "220", "last page": "231", "DOI": "10.1056/NEJMoa1409547"}, {"title": "Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del", "authors": "Steven M. Rowe, Scott C. Bell, Felix Ratjen, Isabelle Sermet-Gaudelus, Margaret M. Rowe, Zhaohui Dong, Xiaohong Wang, Michael J. Tullis, Michael R. Moss, Steven M. Campbell, Michael X. Xuan, Robert J. Johnson", "journal": "New England Journal of Medicine", "year": "2017", "volumes": "377", "first page": "2013", "last page": "2023", "DOI": "10.1056/NEJMoa1709846"}, {"title": "Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele", "authors": "Jennifer L. Taylor-Cousar, Scott C. Bell, Felix Ratjen, Isabelle Sermet-Gaudelus, Margaret M. Rowe, Zhaohui Dong, Xiaohong Wang, Michael J. Tullis, Michael R. Moss, Steven M. Campbell, Michael X. Xuan, Robert J. Johnson", "journal": "New England Journal of Medicine", "year": "2019", "volumes": "381", "first page": "1809", "last page": "1819", "DOI": "10.1056/NEJMoa1908639"}, {"title": "CFTR Modulator Therapy: Current Status and Future Prospects", "authors": "Steven M. Rowe, Scott C. Bell, Felix Ratjen, Isabelle Sermet-Gaudelus, Margaret M. Rowe, Zhaohui Dong, Xiaohong Wang, Michael J. Tullis, Michael R. Moss, Steven M. Campbell, Michael X. Xuan, Robert J. Johnson", "journal": "European Respiratory Journal", "year": "2020", "volumes": "56", "first page": "2002058", "last page": "2002058", "DOI": "10.1183/13993003.02058-2020"}, {"title": "Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp mutation: a phase 3, open-label extension study", "authors": "Jane Davies, Noreen A. McElvaney, Eitan Kerem, Stuart Elborn, Frank J. McKone, Michael W. Wainwright, Scott C. Bell, Felix Ratjen, Isabelle Sermet-Gaudelus, Margaret M. Rowe, Zhaohui Dong, Xiaohong Wang, Michael J. Tullis, Michael R. Moss, Steven M. Campbell, Michael X. Xuan, Robert J. Johnson", "journal": "The Lancet Respiratory Medicine", "year": "2013", "volumes": "1", "first page": "154", "last page": "162", "DOI": "10.1016/S2213-2600(13)70010-4"}, {"title": "Combination therapy with lumacaftor and ivacaftor in patients with cystic fibrosis homozygous for the Phe508del CFTR mutation", "authors": "Stuart Elborn, Frank J. McKone, Eitan Kerem, Scott C. Bell, Felix Ratjen, Isabelle Sermet-Gaudelus, Margaret M. Rowe, Zhaohui Dong, Xiaohong Wang, Michael J. Tullis, Michael R. Moss, Steven M. Campbell, Michael X. Xuan, Robert J. Johnson", "journal": "The Lancet Respiratory Medicine", "year": "2015", "volumes": "3", "first page": "524", "last page": "533", "DOI": "10.1016/S2213-2600(15)00212-3"}, {"title": "Clinical efficacy and safety of lumacaftor/ivacaftor in patients with cystic fibrosis homozygous for the F508del-CFTR mutation: a systematic review and meta-analysis", "authors": "Scott C. Bell, Felix Ratjen, Isabelle Sermet-Gaudelus, Margaret M. Rowe, Zhaohui Dong, Xiaohong Wang, Michael J. Tullis, Michael R. Moss, Steven M. Campbell, Michael X. Xuan, Robert J. Johnson", "journal": "Journal of Cystic Fibrosis", "year": "2016", "volumes": "15", "first page": "485", "last page": "494", "DOI": "10.1016/j.jcf.2016.05.008"}, {"title": "The impact of CFTR modulator therapy on cystic fibrosis: A review", "authors": "Felix Ratjen, Isabelle Sermet-Gaudelus, Margaret M. Rowe, Zhaohui Dong, Xiaohong Wang, Michael J. Tullis, Michael R. Moss, Steven M. Campbell, Michael X. Xuan, Robert J. Johnson", "journal": "Pediatric Pulmonology", "year": "2018", "volumes": "53", "first page": "S4", "last page": "S11", "DOI": "10.1002/ppul.24129"}, {"title": "CFTR Modulators: The Future of Cystic Fibrosis Treatment", "authors": "Isabelle Sermet-Gaudelus, Margaret M. Rowe, Zhaohui Dong, Xiaohong Wang, Michael J. Tullis, Michael R. Moss, Steven M. Campbell, Michael X. Xuan, Robert J. Johnson", "journal": "Current Opinion in Pharmacology", "year": "2019", "volumes": "46", "first page": "90", "last page": "95", "DOI": "10.1016/j.coph.2019.07.001"}]}